CN102179011B - Infrared-ultraviolet composite therapeutic apparatus - Google Patents
Infrared-ultraviolet composite therapeutic apparatus Download PDFInfo
- Publication number
- CN102179011B CN102179011B CN 201110051842 CN201110051842A CN102179011B CN 102179011 B CN102179011 B CN 102179011B CN 201110051842 CN201110051842 CN 201110051842 CN 201110051842 A CN201110051842 A CN 201110051842A CN 102179011 B CN102179011 B CN 102179011B
- Authority
- CN
- China
- Prior art keywords
- ultraviolet
- infrared
- treatment
- infrared ray
- radiation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000001225 therapeutic effect Effects 0.000 title claims abstract description 20
- 239000002131 composite material Substances 0.000 title abstract 5
- 230000000694 effects Effects 0.000 claims abstract description 42
- 230000005855 radiation Effects 0.000 claims description 21
- 230000033228 biological regulation Effects 0.000 claims description 2
- 208000017520 skin disease Diseases 0.000 abstract description 4
- 230000009471 action Effects 0.000 abstract description 2
- 230000008901 benefit Effects 0.000 abstract description 2
- 210000002752 melanocyte Anatomy 0.000 description 23
- 210000003491 skin Anatomy 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 19
- 206010047642 Vitiligo Diseases 0.000 description 17
- 206010040882 skin lesion Diseases 0.000 description 15
- 231100000444 skin lesion Toxicity 0.000 description 15
- 238000011160 research Methods 0.000 description 12
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 10
- 230000006378 damage Effects 0.000 description 9
- 102000003425 Tyrosinase Human genes 0.000 description 8
- 108060008724 Tyrosinase Proteins 0.000 description 8
- 210000004927 skin cell Anatomy 0.000 description 7
- 210000002615 epidermis Anatomy 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 230000036564 melanin content Effects 0.000 description 6
- 239000008187 granular material Substances 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 208000036626 Mental retardation Diseases 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000000049 pigment Substances 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 3
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 3
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 3
- 206010051246 Photodermatosis Diseases 0.000 description 3
- 208000012641 Pigmentation disease Diseases 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 230000033540 T cell apoptotic process Effects 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 210000002510 keratinocyte Anatomy 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000036542 oxidative stress Effects 0.000 description 3
- 230000008845 photoaging Effects 0.000 description 3
- 230000035790 physiological processes and functions Effects 0.000 description 3
- 230000019612 pigmentation Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 2
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 2
- 206010048768 Dermatosis Diseases 0.000 description 2
- 102100033902 Endothelin-1 Human genes 0.000 description 2
- 101800004490 Endothelin-1 Proteins 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 102000016621 Focal Adhesion Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108010067715 Focal Adhesion Protein-Tyrosine Kinases Proteins 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000008642 heat stress Effects 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 238000001126 phototherapy Methods 0.000 description 2
- 238000000554 physical therapy Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000000015 thermotherapy Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 108060003345 Adrenergic Receptor Proteins 0.000 description 1
- 102000017910 Adrenergic receptor Human genes 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 206010015152 Erythema Ab Igne Diseases 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 241000381142 Pachydermia Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108091093078 Pyrimidine dimer Proteins 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- ASJWEHCPLGMOJE-LJMGSBPFSA-N ac1l3rvh Chemical compound N1C(=O)NC(=O)[C@@]2(C)[C@@]3(C)C(=O)NC(=O)N[C@H]3[C@H]21 ASJWEHCPLGMOJE-LJMGSBPFSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000011262 co‐therapy Methods 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000035614 depigmentation Effects 0.000 description 1
- 230000036557 dermal exposure Effects 0.000 description 1
- 231100000823 dermal exposure Toxicity 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 108010007093 dispase Proteins 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000003328 fibroblastic effect Effects 0.000 description 1
- 210000003953 foreskin Anatomy 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000003760 hair shine Effects 0.000 description 1
- CPBQJMYROZQQJC-UHFFFAOYSA-N helium neon Chemical compound [He].[Ne] CPBQJMYROZQQJC-UHFFFAOYSA-N 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003447 ipsilateral effect Effects 0.000 description 1
- 238000013332 literature search Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 238000000879 optical micrograph Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 231100000760 phototoxic Toxicity 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 230000001185 psoriatic effect Effects 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000011450 sequencing therapy Methods 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 230000037070 skin defense Effects 0.000 description 1
- 230000004215 skin function Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000036561 sun exposure Effects 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 229910052724 xenon Inorganic materials 0.000 description 1
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 1
- SFVVQRJOGUKCEG-OPQSFPLASA-N β-MSH Chemical compound C1C[C@@H](O)[C@H]2C(COC(=O)[C@@](O)([C@@H](C)O)C(C)C)=CCN21 SFVVQRJOGUKCEG-OPQSFPLASA-N 0.000 description 1
Images
Landscapes
- Radiation-Therapy Devices (AREA)
Abstract
The invention discloses an infrared-ultraviolet composite therapeutic apparatus, which is used for treating skin diseases through the combined action of infrared rays and ultraviolet rays. The infrared-ultraviolet composite therapeutic apparatus comprises an infrared and ultraviolet double light source, a lamp cover, a movable supporting rod, a power supply and a control platform, wherein the control platform comprises a double-switch control system, a temperature control system and a time control system. The infrared-ultraviolet composite therapeutic apparatus can irradiate the skin of each part of the human body and effectively treat various skin diseases, such as leucoderma and the like; and the infrared-ultraviolet composite therapeutic apparatus has the advantages of simpleness, safety and reliability in operation, obvious treatment effect, easiness in being accepted by patients, and the like.
Description
Technical field
The present invention relates to armarium, particularly a kind of with infrared ray and ultraviolet combined effect in the optical radiation therapeutic instrument of human body skin take the treatment vitiligo as main multiple dermatosis.
Background technology
The color of human skin main with epidermis in melanocyte (melanocytes, MC) synthesize melanocyte and melanocyte and be passed to that keratinocyte (keratinocytes, KC) is relevant on every side.Under the impact of solar radiation, Skin Cell can reduce/avoid by the adjustment and control system of self complexity the damage that solar radiation may cause cell, and wherein melanin granule is being played the part of the effect of similar superoxide dismutase.Melanin granule stops the damage of cell DNA, albumen and membrane lipid by absorbing, disperse products of oxidative stress, removing free radical, and then plays important skin defence and protective effect.Dermal exposure can cause skin tanning, photoaging and light canceration under daylight.It is main relevant with ultraviolet (ultraviolet, UV), especially ultraviolet B radiation (ultraviolet B, UVB) that research previously thinks that these change.But recently, increasing evidence shows that energy matter-Re main in the daylight (infrared ray) also has the effect of similar UV to Skin Cell, and same intermittent fever (infrared ray) also can increase Skin Cell to the toleration of UV.Although people have done a large amount of research in the UV radiation aspect the impact of MC physiology and pathologic function at present, but heat (infrared ray) is at the early-stage on the research of MC physiological function impact, and this is providing a wide space for us aspect thermotherapy treatment pigmented dermatosis.We know that skin is the important barrier that the protecting human body internal is not subjected to external environment damage (such as daylight, ray, mechanical stimulus etc.).Acute Sunlight exposure can cause light sunburn and light tanned; The daylight long-term irradiation can cause the photic damage of Skin Cell, produces photoaging and light canceration.Short-term or accept for a long time solar radiation no matter, the most obvious variation of skin is exactly that irradiated site forms erythema and pigmentation.Research finds that the melanin granule that melanocyte produces is the human body protective agent natural to daylight.Melanin granule passes through to absorb daylight, disperses products of oxidative stress, removes free radical, thereby stops the damage of sun-induced cell DNA, albumen and membrane lipid, and then plays important skin defense reaction.Pigmentation is exactly the result that skin directly is on the defensive to environmental stimuluses such as solar radiations.Daylight generally includes UV (290-400nm), visible light (400-760nm) and infrared ray (760nm-1mm) three parts.Research previously thinks that UV radiation especially UVB is the main matter that sun exposure causes all manifold effects of skin.In the past few years, the research of a large amount of daylight impression skin functions also mainly launches around UV.But recently, scholars recognize that gradually the infrared ray (mainly being the heat effect of its generation) that accounts for daylight gross energy 54.3% also has the effect of similar UV to skin, has positive protective effect with intermittent fever to the radiation-induced skin injury of UV.
People just find that some people that warm oneself by a fire for a long time or sit around by stove can get erythema ab igne a long time ago, and clinical manifestation is that the changes such as netted pigmentation, telangiectasis appear in the position that is exposed to heat.It is similar that these change the skin photoage that causes with UV.The same with UV, slow fever exposes and can cause directly that also epidermis thickens, pigment increases, corium elastic fibers tissue injury, even causes the Skin Cell canceration.Increasing research evidence shows that heat (infrared ray) exposes meeting coup injury cell and crganelle film, causes DNA damage, thereby directly causes skin melanism, aging and canceration, and can strengthen skin tanning, photoaging and the photic carcinous effect that UV causes.In addition, heat (infrared ray) also has increases Skin Cell to the effect of UV toleration.Research is found to immerse immediately after UVB shines skin in 40 ℃ of water and to be immersed in 30 ℃ of water its erythema than immediately and can shorten incubation period.But its erythemal effect of inducing can be than weakening in 30 ℃ of water; Menezes and Danno etc. confirm respectively that also infrared ray can obviously suppress the radiation-induced skin KC apoptosis of UVB and fibroblastic death.Boreham etc. find that heating bath has obviously increased toleration and the tanned reaction of skin to solar radiation in the psoriatic process of application heating bath (40 ℃ of water-baths, 2 times weekly, 8 all 1 courses for the treatment of) treatment.
The applicant also realizes in therapy of vitiligo for many years, and herbal fomentation (45 ℃, 30min, 1 times/day) can obviously improve leukodermic secondary color rate.The recent result of study of this seminar also tentative confirmation heat stress (〉=39 ℃, effect MC 60min) has direct melanotropin anabolic effect, has compared significant difference (P＜0.05) with the blank group, and this acts on 42 ℃ and reaches maximum.Above-mentioned research all points out us heat may equally have important regulating action to the skin pigment system with UV, may have certain collaborative and protective effect between the two.Based on this, the applicant in 2008 national Dermatology Professional Committee's combination of Chinese and Western medicine pigment disease group " vitiligo practice guidelines " revision can proposition with thermotherapy as a kind of new therapy of vitiligo method, this proposal has obtained participant expert's consistent approval.So far, people have done a large amount of experimentatioies with regard to UV to the impact of MC physiological function, but the relation of heat and MC physiological function is known little about it.By literature search, we find only to have two pieces of relevant reports and result also to be not quite similar abroad, domesticly then still find no similar research.Nakazawa in 1998 etc. have at first compared people's epidermis MC to two kinds of main exogenous stimulation UVB and the cell effect of heat, found that: (42 ℃ of heat, 60min) and after UVB (20mJ/cm2) radiation treatment purification cultivates people's epidermis MC 3d, the MC dendron increases prolongation, cell space increases, the synthetic increase of cell tyrosinase activity and melanocyte, the rate of increase descend, but return to the Normal group level after 6 days; Heat and UVB have all promoted to have in KC-MC co-culture system and the organization engineering skin MC quantity of functional activity to increase.
We prove that by experiment the melanocyte of independent use infrared ray or ultraviolet radiation In vitro culture all can make the tyrosinase activity of cell and melanin content increase at present; after if two kinds of light sources of use in conjunction successively shine the melanocyte of In vitro culture; not only melanocytic tyrosinase activity and melanin content shine separately apparently higher than two kinds of light sources, and ultrared heat effect can also protect ultraviolet to melanocytic destruction effectively.
Although the vitiligo pathogenesis it be unclear that, but its main manifestations is skin pigment to be taken off to lose or go down and is the department of dermatologry common disease of feature, tissue pathology checking confirms that patients with vitiligo skin lesion basal layer melanocyte reduces or disappearance, this is the pathologic basis of vitiligo skin lesion formation just, so we alleviate exactly the melanocytic destruction in skin lesion district and strengthen the remaining melanocytic activity in skin lesion district the main principle when the treatment vitiligo, make its propagation, break up and move to the position of depigmentation, thereby reach the effect that makes the vitiligo secondary color.Although but the not clear several related causes approved by academia at present of the leukodermic real cause of disease have: autoimmune disorder, oxidative stress, theory of heredity etc., so we treat the mode that vitiligo generally all adopts Drug therapy, naturopathy and the therapeutic alliance of operative treatment several different methods.And the treatment vitiligo of using clinically now gets physical therapy apparatus and comprises the types such as narrow general ultraviolet B radiation (NB-UVB), 308nm excimer laser, long wave ultraviolet (UVA), mental retardation He-Ne Lasers, not yet sees infrared ray and infrared ray and the leukodermic equipment of ultraviolet co-therapy used.
NB-UVB can promote melanocyte proliferation by stimulating keratinocyte release basic fibroblast growth factor (bFGF) and endothelin-1 (ET-1), simultaneously it can also improve the activity of the MMP-2 (MMP-2) of melanocyte self and local focal adhesion kinase (FAK) and accelerate melanocytic migration, to reach the purpose that makes vitiligo skin lesion secondary color.In addition, NB-UVB can also make local skin T lymphocyte DNA form thymine dimer, the inducer T lymphocyte apoptosis, thus the immunne response that suppresses local skin also is one of leukodermic mechanism of action for the treatment of.The 308nm excimer laser is a kind of chlorination xenon (XeCl) excimer laser, and its wavelength is in the UVB scope.Research finds that the 308nm excimer laser can induce the T Lymphocyte Apoptosis of skin lesion local infiltration effectively, the effect of its inducer T lymphocyte apoptosis even be better than NB-UVB.UVA is the leukodermic physiotherapy for the treatment of of using clinically the earliest, it treats the machine-processed basic identical of leukodermic mechanism and other phototherapy, mainly be to reach a leukodermic purpose for the treatment of by the cellullar immunologic response of inhibition skin lesion part and for melanocyte provides a favourable propagation microenvironment, UVA has used a century nearly in treatment vitiligo field, its curative effect is to be worth sure, but its side effect is too much, so its position is substituted by NB-UVB and 308nm excimer laser gradually to a certain extent.Mental retardation helium neon laser vitiligo also is not widely used in clinical, finds with mental retardation He-Ne Lasers 3.0J/cm but there is the scholar to do in this respect some tentative researchs
2, 1～2 treatment 40 routine stable incidence segmental vitiligo weekly, after the mean treatment 17 times, skin lesion begins to occur secondary color, have 60% patient through secondary color area after the continuous treatment greater than 50%.In addition this scholar compared also that the blood flow at skin lesion positions before and after the treatment changes and the situation of replying of adrenoceptor after think that the mental retardation He-Ne Lasers may be to reach by repair function unusual sympathetic nerve to treat leukodermic purpose.
Although the curative effect of above therapeutic equipment still can, the side effect that its when treatment occurs still can not be despised, and sometimes patient's health is worked the mischief, and is unfavorable for the rehabilitation of patient disease.These therapeutic equipments of now clinical practice all are that maximization equipment operating power is large in addition, dosage control requires high, need the professional and technical personnel to operate, can not be used for family uses, the patient must regularly receive treatment to hospital, the very inconvenient patient compliance that causes is not high, thereby affects therapeutic effect.In addition, we also do not see and use separately clinically the leukodermic equipment of infrared therapy, so the present invention provides a kind of new treatment theory for leukodermic treatment especially not still to an improvement of present clinical other treatment instrument.
Summary of the invention
The object of the invention is to remedy the deficiency of single ultraviolet aspect the treatment vitiligo, the synergism of using infrared ray (mainly being heat effect) and ultraviolet promotion melanocyte activity improves the secondary color effect of the skin lesion treatment of patients with vitiligo, utilize simultaneously thermal effect should be able to obviously reduce ultraviolet to melanocytic destruction, thereby reduce the side effect of existing equipment treatment, this equipment is configured to a kind of medical-type and portable domestic type therapeutic instrument in addition, make things convenient for patient's use, thereby improved the compliance of patient treatment.
The objective of the invention is to be achieved through the following technical solutions:
This therapeutic instrument comprises infrared ray, the two light sources of ultraviolet, lampshade, mobilizable support bar and control station.Two light sources are sent by two identical infrared ray and quartz burner respectively, movable support bar has two movable Metallic rod to consist of (like the support bar of desk lamp), control station is provided with each one of two light source switch, one of infrared temperature control handle, each one of infrared ray and ultraviolet irradiation time setting knob.
Wherein: the lampshade that luminous lamp tube is installed can be done 360 ° of rotations around the longitudinal axis of fluorescent tube, make things convenient for the not ipsilateral skin lesion of patient exposure health, lampshade also can be done 180 ° of rotations around the transverse axis of fluorescent tube simultaneously, the height that movable support bar can the up-down adjustment light source in addition, this design from three kinds of different dimensions adjusted light source positions can be satisfied the treatment needs to any position skin lesion.
Control system of the present invention adopts the mode of separating control, and namely the switch of infrared light supply and ultraviolet source separates, and the exposure time control system of infrared light supply and ultraviolet source is separated, and this separation control mode is conducive to two kinds of light sources and carries out sequential radiation treatment.The present invention adds and has used the infrared temperature control system in addition, thereby makes the ultrared thermal effect would not be too high and cause skin scald or cross low and do not reach therapeutic purposes.
Description of drawings
Fig. 1: the melanocyte of In vitro culture purification
Fig. 2: melanocytic Masson-Fontana dyeing is identified
Fig. 3: the heat stress of different temperatures is on the impact of normal person's melanocyte proliferation rate of In vitro culture
Fig. 4: the UVB irradiation of various dose is on the impact of normal person's melanocyte proliferation rate of In vitro culture
Fig. 5: different condition is on the impact of melanocyte tyrosinase activity and melanin content
Annotate: * has compared significant difference P＜0.05 with normal control, UVB and heat treatment group UVB or heat treatment group tyrosinase activity; # has compared significant difference P＜0.05 with normal control, UVB and heat treatment group melanocyte amount.
Fig. 6: surface structure sketch map of the present invention.(numeral refers in the accompanying drawing: 1, infrared light supply switch; 2, ultraviolet source switch; 3, infrared temperature control knob; 4, infrared light exposure time setting device; 5, ultraviolet light irradiation time-setting mechanism; 6, lampshade; 7, infrared light supply fluorescent tube; 8, ultraviolet source fluorescent tube; 9, control station; 10, mobilizable support bar; 11, power supply)
Fig. 7: principle schematic of the present invention
Fig. 8: the floor map of two light sources
Fig. 9: control station sketch map
The specific embodiment
The invention will be further described below in conjunction with accompanying drawing.
Once how we confirm by experiment that ultrared heat effect and ultraviolet are to melanocytic collaborative facilitation to paper.
1, the melanocytic cultivation of normal person and going down to posterity: normal person's foreskin pruned help pachydermia, after the Dispase enzymic digestion with 5g/L, separate corium and epidermis, epidermis is with the digestion of 2.5g/L tryptic digestive juice and make single cell suspension, put the melanocyte culture fluid and (contain 5% FBS, 100U/ml penicillin and 100ug/ml streptomycin, the CDMB153 culture medium of bFGF) in, at 37 ℃, 5%CO
2Cultivate in the incubator, behind cell confluent cultures bottle, go down to posterity and cultivate the melanocyte that obtains purification, as shown in Figure 1.
2, melanocytic Masson-Fontana dyeing is identified: with the 3rd generation cell suspending liquid concentration transfer to 5 * 10
3/ ml is inoculated in the culture dish that diameter is 35mm, and every ware inoculation 1ml dyes behind the 24h.The optical microphotograph Microscopic observation, the melanin granule in the cell cytosol is black, and nucleus takes on a red color, and confirms that the cell that we obtain is melanocyte.As shown in Figure 2.
3, mtt assay is measured the ultraviolet radiation of different temperatures and various dose to the impact of the melanocytic proliferation activity of normal person of In vitro culture: select the 3rd generation cell, with 6 * 10
4The density of/ml is inoculated in respectively in the culture dish of 13 35mm, every hole 1.5ml.Behind the cell inoculation 24h, wherein 1 group at 37 ℃ of normal cultivate (matched groups), and wherein 5 groups respectively at 39 ℃, 41 ℃, 42 ℃, 43 ℃, 45 ℃, intervene under 5 different temperatures, intervene 1h every day, intervene continuously 3d; Other 7 groups respectively at 20mJ/cm
2, 30mJ/cm
2, 40mJ/cm
2, 50mJ/cm
2, 70mJ/cm
2, 90mJ/cm
2, 120mJ/cm
2Intervene under 7 different irradiation doses, intervene continuously 3 days all intervention group after last is intervened 20h, add the MTT solution of 5g/L in each culture dish, hatch 4h for 37 ℃.Discard liquid adding dimethyl sulfoxide (DMSO) in the culture plate, every ware 2.25ml, vibration 15min, under the 492nm wavelength, detect optical density value and calculate the rate of increase: cell proliferation rate (%)=(experimental group mean light absorbency-blank mean light absorbency)/(matched group mean light absorbency-blank mean light absorbency) * 100%, select suitable intervention condition as the condition of next step experiment, shown in accompanying drawing 3,4.
4, tyrosinase activity and melanin content are measured: will cultivate the 4th generation cell to transfer to concentration be 2 * 105/ml, be inoculated in respectively in 4 100mm culture dishs with every ware 4mL, behind the 24h respectively to adopting 37 ℃, 5%CO
2Normally hatch 42 ℃, 5%CO
2Condition lower every day of 1h intervenes 3d, 40mJ/cm continuously
2UVB every day 1 continuous intervention 3d and 42 ℃ of every days, 5%CO
2Horse back 40mJ/cm after intervention is finished under the condition
2UVB intervenes continuously and intervened 3 days, all groups are after last is intervened 24h, measure respectively activity and the melanin content of cell tryrosinase with reference to the method for Maeda and Virador etc., select 492nm wavelength place colorimetric, with the blank well zeroing, survey each hole absorbance and calculate the cell tyrosinase activity and the melanin content rate of increase.
Cell tyrosinase activity rate of increase=[(experimental group mean light absorbency-blank mean light absorbency) ÷ (matched group mean light absorbency-blank mean light absorbency)-1] * 100%.
Melanocyte synthesizes rate of increase=[(cell number of experimental group absorbance ÷ test group) ÷ (cell number of matched group absorbance ÷ matched group)-1] * 100%, obtains different interventions to the impact of melanocyte activity.As shown in Figure 5.
Secondly, detailed structure of the present invention and the workflow introduced
Shown in accompanying drawing 6,8,9, the present invention includes infrared ray, the two light sources of ultraviolet, movable support bar 10 and control station 9.The light source luminescent pipe places in the lampshade 6, lampshade 6 is fixed on the movable support bar 10 by a head, power supply and control circuit are along support bar 10 travelings, the lower end of support bar 10 is fixed on the control station 9, is respectively equipped with infrared light supply switch 1, ultraviolet source switch 2, infrared temperature control knob 3, infrared light exposure time setting device 4, ultraviolet source exposure time setting device 5 on the control station 9.Described infrared temperature control knob is controlled the temperature of infrared light supply by regulating and control voltage, described time-setting mechanism possesses the timer of control irradiation dose.
Workflow of the present invention: 1. light source position is regulated at the patient position for the treatment of as required; 2. open the infrared control switch, regulate time and the temperature that needs treatment according to dosage subordinate list (not providing); 3. the skin lesion that waits equipment work after 5 minutes needs to be carried out radiation treatment places the position of dosage subordinate list regulation, at first skin lesion is carried out infrared therapy; 4. infrared therapy is turned off the infrared light supply switch after finishing, and opens the ultraviolet source switch, regulates the used time of ultraviolet irradiation by dosage subordinate list (not providing) equally, carries out the ultraviolet light treatment; 5. treatment is turned off power supply after finishing, and whole treatment flow process finishes.
Because the sequential therapy of irradiation under ultraviolet ray behind the first Infrared irradiation has been adopted in this invention, not only can effectively improve the colour of skin effect of white macula skin lesion, and reduced the phototoxic action of ultraviolet light to Skin Cell, reduced the side effect of phototherapy, this also is that the present invention is than the advantage place of other similar therapeutic equipments of having used clinically at present.
Claims (5)
1. the leukodermic therapeutic instrument for the treatment of is characterized in that, this therapeutic instrument is comprised of infrared ray and the two light sources of ultraviolet B radiation, lampshade, mobilizable support bar and control station; The two light sources of described infrared ray and ultraviolet B radiation place described lampshade jointly, and described lampshade is fixed on described mobilizable support bar, and described support bar is fixed on the described control station; Described control station comprises biswitch control system, infrared temperature control system and time control system; The described infrared ray light source of being connected with ultraviolet B radiation connects with the gauge tap of being connected respectively, and biswitch is controlled respectively the luminous of two light sources; Described time controlled system is used for setting described infrared ray and ultraviolet B radiation exposure time.
2. the leukodermic therapeutic instrument for the treatment of according to claim 1 is characterized in that, the two light sources of described infrared ray and ultraviolet B radiation are luminous tube, place described lampshade, and lampshade is fixed on the described support bar by the device of an activity.
3. the leukodermic therapeutic instrument for the treatment of according to claim 1 is characterized in that, described mobilizable support bar can be done the activity that upper and lower makes progress, and can arrive the effect that can play fixing two light sources behind the assigned address at described pair of light source.
4. the leukodermic therapeutic instrument for the treatment of according to claim 1 is characterized in that, described infrared temperature control system is to control the temperature of infrared light supply by regulation and control voltage.
5. leukodermic therapeutic instrument according to claim 1 is characterized in that, described time controlled system possesses the timer of control irradiation dose.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110051842 CN102179011B (en) | 2011-03-04 | 2011-03-04 | Infrared-ultraviolet composite therapeutic apparatus |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110051842 CN102179011B (en) | 2011-03-04 | 2011-03-04 | Infrared-ultraviolet composite therapeutic apparatus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102179011A CN102179011A (en) | 2011-09-14 |
| CN102179011B true CN102179011B (en) | 2013-03-13 |
Family
ID=44565413
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201110051842 Active CN102179011B (en) | 2011-03-04 | 2011-03-04 | Infrared-ultraviolet composite therapeutic apparatus |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102179011B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11474038B2 (en) * | 2018-02-05 | 2022-10-18 | Shiseido Company, Ltd. | Method for evaluating protective effect against external damage to skin |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2492883C1 (en) * | 2011-12-29 | 2013-09-20 | Николай Николаевич Новиков | Ultraviolet and infrared phototherapeutic apparatus |
| CN104383644A (en) * | 2014-12-18 | 2015-03-04 | 邱有英 | Desk-lamp-type infrared physiotherapeutic instrument |
| CN105276518B (en) * | 2015-10-27 | 2018-04-17 | 刘红 | A kind of health-nutrition LED light source device |
| CN106798727A (en) * | 2016-12-29 | 2017-06-06 | 上海交通大学 | A drug delivery method using infrared light to increase the biological activity of small interfering RNA sequences in skin |
| CN106821981A (en) * | 2016-12-29 | 2017-06-13 | 上海交通大学 | A kind of infrared light increases activity RNA（RNAa）Sequence enters skin and produces the medication of bioactivity |
| WO2018121674A1 (en) * | 2016-12-29 | 2018-07-05 | 上海交通大学 | Administration method using infrared light to enhance biological activity of rna sequence in skin |
| CN109966650A (en) * | 2017-12-28 | 2019-07-05 | 广东百视特照明电器有限公司 | A kind of Led herpes treatment apparatus and treatment method |
| CN115091668A (en) * | 2022-05-27 | 2022-09-23 | 国营芜湖机械厂 | Dual light source photo-thermal curing method suitable for emergency repair of outfield complex structure |
| CN116617586B (en) * | 2023-05-25 | 2024-01-23 | 北京工业大学 | Light control system for ultraviolet crosslinking auxiliary infrared light irradiation, application and method |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1859947A (en) * | 2003-09-30 | 2006-11-08 | 库雷莱特有限公司 | Phototherapeutic treatment of skin conditions |
| CN2875490Y (en) * | 2005-01-19 | 2007-03-07 | 苏柏衡 | Radiation Therapy Apparatus |
| WO2008110963A1 (en) * | 2007-03-09 | 2008-09-18 | Philips Intellectual Property & Standards Gmbh | Phototherapy apparatus for treatment of skin disorders |
| CN201337766Y (en) * | 2008-12-31 | 2009-11-04 | 张洪冰 | Photodynamic energy therapeutic instrument for leucoderma |
| CN101721773A (en) * | 2008-10-29 | 2010-06-09 | 北京市赛思创科技发展有限责任公司 | Equipment for treating vitligo by utilizing turnable lattice dual wavelength laser |
| WO2011001344A2 (en) * | 2009-06-30 | 2011-01-06 | Koninklijke Philips Electronics N.V. | Light treatment system |
-
2011
- 2011-03-04 CN CN 201110051842 patent/CN102179011B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1859947A (en) * | 2003-09-30 | 2006-11-08 | 库雷莱特有限公司 | Phototherapeutic treatment of skin conditions |
| CN2875490Y (en) * | 2005-01-19 | 2007-03-07 | 苏柏衡 | Radiation Therapy Apparatus |
| WO2008110963A1 (en) * | 2007-03-09 | 2008-09-18 | Philips Intellectual Property & Standards Gmbh | Phototherapy apparatus for treatment of skin disorders |
| CN101721773A (en) * | 2008-10-29 | 2010-06-09 | 北京市赛思创科技发展有限责任公司 | Equipment for treating vitligo by utilizing turnable lattice dual wavelength laser |
| CN201337766Y (en) * | 2008-12-31 | 2009-11-04 | 张洪冰 | Photodynamic energy therapeutic instrument for leucoderma |
| WO2011001344A2 (en) * | 2009-06-30 | 2011-01-06 | Koninklijke Philips Electronics N.V. | Light treatment system |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11474038B2 (en) * | 2018-02-05 | 2022-10-18 | Shiseido Company, Ltd. | Method for evaluating protective effect against external damage to skin |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102179011A (en) | 2011-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102179011B (en) | Infrared-ultraviolet composite therapeutic apparatus | |
| Hamblin | Mechanisms and applications of the anti-inflammatory effects of photobiomodulation | |
| Wurtman | The effects of light on the human body | |
| Azeemi et al. | The mechanistic basis of chromotherapy: Current knowledge and future perspectives | |
| Tsai et al. | Low-level light therapy potentiates NPe6-mediated photodynamic therapy in a human osteosarcoma cell line via increased ATP | |
| Sowa et al. | Optical radiation in modern medicine | |
| Chen et al. | Irradiance plays a significant role in photobiomodulation of B16F10 melanoma cells by increasing reactive oxygen species and inhibiting mitochondrial function | |
| Sharma et al. | Role of opsins and light or heat activated transient receptor potential ion channels in the mechanisms of photobiomodulation and infrared therapy | |
| Lin et al. | Clinical effects of laser acupuncture plus Chinese cupping on the pain and plasma cortisol levels in patients with chronic nonspecific lower back pain: a randomized controlled trial | |
| US10960224B2 (en) | Trans-orbital infrared light therapy | |
| Holick et al. | Biologic Effects of Light: Proceedings of the Symposium, Atlanta, Georgia, USA, October 13–15, 1991 | |
| CN105662905A (en) | Application of dihydromyricetin in preparation of skin-care products or drugs for preventing and treating optical skin injuries | |
| Li et al. | Light exposure and its applications in human health | |
| Yao et al. | Transcranial near-infrared laser therapy in improving cognitive recovery of function following traumatic brain injury | |
| KR20080094642A (en) | Chair type Meridian Light Therapy | |
| SK5457Y1 (en) | Nasal applicator for intranasal laser irradiation of blood | |
| Jung et al. | Photobiomodulation and its therapeutic potential in sleep disturbances | |
| Wu et al. | Application of photobiomodulation therapy in acupuncture | |
| KR101025473B1 (en) | Meridian Light Therapy | |
| Aviña et al. | Safe Mitochondrial Activation Through Photobiomodulation: Distinct Red and Near‐Infrared Responses in Normal and Malignant Cells | |
| Kellogg | Light Therapeutics | |
| Harris | Studies on the biological action of light | |
| Lim | The Potential of intranasal light therapy for brain stimulation | |
| CN105561478A (en) | Application of far infrared water body thermotherapy | |
| Li et al. | Phototherapy and optogenetic stimulation improve cognitive function in sleep-deprived mice |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |